Direxion Daily Energy Bull 2X Shares ETF
ERX
Energy Select Sector SPDR Fund
XLE
Direxion Daily Financial Bull 3X Shares ETF
FAS
4
Invesco DB Commodity Index Tracking Fund
DBC
5
Ultra Financials Proshares
UYG
US Stock MarketDetailed Quotes
Immix Biopharma (IMMX)
- 8.550
- +0.380+4.65%
Close Jul 30 16:00 ET
- 8.620
- +0.070+0.82%
Post 20:01 ET
608.67MMarket Cap-9.29P/E (TTM)
8.630High8.260Low1.30MVolume8.280Open8.170Prev Close11.05MTurnover2.29%Turnover RatioLossP/E (Static)71.19MShares12.14052wk High7.22P/B485.48MFloat Cap1.94052wk Low--Dividend TTM56.78MShs Float12.140Historical High--Div Yield TTM4.53%Range %0.680Historical Low8.506Avg Price1Lot Size
IMMX Stock Chart
Full Hours
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
IMMX Orderflow
Unit: --
IMMX Orderflow Trend
IntradayDayWeekMonth
No Data
Immix Biopharma (IMMX) News
Needham Initiates Immix Biopharma(IMMX.US) With Buy Rating, Announces Target Price $21
Express News | Needham Initiates Coverage On Immix Biopharma With Buy Rating, Announces Price Target of $21
Express News | Immix Biopharma Inc : Needham Initiates Coverage With Buy Rating; Target Price $21
Express News | Immix Biopharma Shares Are Trading Lower. A Report Suggested That a Fugitive Worked as an Executive for the Company
Immix Biopharma Drops After Chief Medical Officer Terminated
Immix Biopharma Announces Termination of CMO Richard Graydon
Immix Biopharma (IMMX) Stock Forum
$Immix Biopharma (IMMX.US)$ Immix Biopharma Announces Closing of $150 Million Underwritten Offering of Common Stock
GlobeNewswire
– Financing includes leading U.S. biotechnology institutional investors and mutual funds –
LOS ANGELES, CA, May 22, 2026 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. ("ImmixBio", "Company", "We" or "Us" or "IMMX"), a global leader in AL Amyloidosis, today announced the closing of its previously announced underwritten registered offering of 16,778,524 ...
GlobeNewswire
– Financing includes leading U.S. biotechnology institutional investors and mutual funds –
LOS ANGELES, CA, May 22, 2026 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. ("ImmixBio", "Company", "We" or "Us" or "IMMX"), a global leader in AL Amyloidosis, today announced the closing of its previously announced underwritten registered offering of 16,778,524 ...
$Immix Biopharma (IMMX.US)$ Immix Biopharma Prices Underwritten Registered Offering Of 16,778,524 Shares At $8.94 Per Share
Benzinga
2m
The gross proceeds to Immix from the offering, before deducting the underwriting discounts, commissions and other offering expenses, are expected to be $150 million. The offering is expected to close on or about May 22, 2026, subject to the satisfaction of customary closing conditions.
Immix int...
Benzinga
2m
The gross proceeds to Immix from the offering, before deducting the underwriting discounts, commissions and other offering expenses, are expected to be $150 million. The offering is expected to close on or about May 22, 2026, subject to the satisfaction of customary closing conditions.
Immix int...
3
$Immix Biopharma (IMMX.US)$ Immix Biopharma Announces 95% Complete Response Rate in Interim Update From Relapsed/refractory AL Amyloidosis Clinical Trial NEXICART-2
GlobeNewswire
– Of first 20 patients, all four MRD-negative patients have converted to complete response (CR) –
– CR rate now 95% (19 of 20 patients) –
– All CRs reached within 1 year of follow-up post-dosing –
– No relapses to-date observed for patients who have reached CR –
– All subsequently enrolled patients for whom MRD resul...
GlobeNewswire
– Of first 20 patients, all four MRD-negative patients have converted to complete response (CR) –
– CR rate now 95% (19 of 20 patients) –
– All CRs reached within 1 year of follow-up post-dosing –
– No relapses to-date observed for patients who have reached CR –
– All subsequently enrolled patients for whom MRD resul...
1
$Immix Biopharma (IMMX.US)$ I bought in at $7.36 ...immediately it dropped $1
$Immix Biopharma (IMMX.US)$ Immix Biopharma Announces Closing of Upsized $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
1 MINUTE AGO, 5:45 PM EST
VIA GLOBENEWSWIRE
– Financing includes leading U.S. biotechnology institutional investors and mutual funds –
LOS ANGELES, CA, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. ("ImmixBio", "Company", "We" or "Us" or "IMMX"), a global leader in relapsed/refractory AL Amyloidosis, today announced the closing of its p...
1 MINUTE AGO, 5:45 PM EST
VIA GLOBENEWSWIRE
– Financing includes leading U.S. biotechnology institutional investors and mutual funds –
LOS ANGELES, CA, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. ("ImmixBio", "Company", "We" or "Us" or "IMMX"), a global leader in relapsed/refractory AL Amyloidosis, today announced the closing of its p...
1
Read more
Market Insights
Hot Topics Hot Topics
Surf the ETF wave: Master the market with wisdom & ease!
As the financial landscape evolves, ETFs have emerged as a versatile tool for investors seeking to grow wealth, diversify portfolios, and st
102362254
Sep 4, 2024 16:25
Sharing my long-term ETF story
mr_cashcow
Sep 11, 2024 10:30
Low cost ETF is the way to go! September P/L challenge #6 (200words count entry)